Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Prothena Corporation plc

Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report Second Quarter 2025 Financial Results on August 4
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Corporate Restructuring
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports First Quarter 2025 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report First Quarter 2025 Financial Results on May 8
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Board of Directors Update
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports Third Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report Third Quarter 2024 Financial Results on November 12
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Leadership Team Updates
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports Second Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report Second Quarter 2024 Financial Results on August 8
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports First Quarter 2024 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report First Quarter 2024 Financial Results on May 8
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Appoints David Ford to Newly Created Chief People Officer Position
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
From Prothena Corporation plc
Via Business Wire
Tickers PRTA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.